{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-25-000081","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.272549+00:00","generated_at":"2026-05-16T21:20:37.308081+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission","bullets":["Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).","Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.","FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.","Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.","Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-25-000081","json":"https://secwatch.observer/filing/0001730463-25-000081.json","markdown":"https://secwatch.observer/filing/0001730463-25-000081.md","text":"https://secwatch.observer/filing/0001730463-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/0001730463-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autl-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:20:37.308081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}